Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) CFO Karthik Radhakrishnan acquired 1,550 shares of the business's stock in a transaction on Monday, October 28th. The stock was acquired at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the transaction, the chief financial officer now owns 1,550 shares of the company's stock, valued at approximately $25,187.50. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Monopar Therapeutics Trading Down 9.5 %
Shares of NASDAQ MNPR opened at $14.67 on Thursday. The stock has a fifty day simple moving average of $5.70 and a two-hundred day simple moving average of $4.19. Monopar Therapeutics Inc. has a 1-year low of $1.37 and a 1-year high of $38.50. The firm has a market cap of $51.64 million, a price-to-earnings ratio of -6.38 and a beta of 1.26.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Analysts forecast that Monopar Therapeutics Inc. will post -1.93 EPS for the current year.
Wall Street Analysts Forecast Growth
625,000% Gain
From Crypto Swap Profits | Ad
Imagine swapping your daily coffee expense for a future free of financial worries.
It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market.
Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
>> Dive into the Workshop Here
A number of equities research analysts have recently commented on MNPR shares. Rodman & Renshaw began coverage on Monopar Therapeutics in a research note on Friday, October 11th. They set a "buy" rating and a $50.00 target price on the stock. HC Wainwright raised their price objective on shares of Monopar Therapeutics from $2.00 to $6.00 and gave the stock a "buy" rating in a report on Wednesday, August 14th.
Check Out Our Latest Report on Monopar Therapeutics
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
